Volume 45 Issue 1, January 2024

Cover Credit: DZ2002, a reversible inhibitor of type III S-adenosyl-L-homocysteine hydrolase, attenuates TNF-α-induced NF-κB signaling by suppressing the degradation and phosphorylation of IκB, along with NF-κB p65 phosphorylation and nuclear translocation. Additionally, DZ2002 inhibits the activation of molecules in the STAT3-PI3K-Akt pathway, suppressing the secretion of inflammatory cytokines and pro-angiogenic factors. These findings strongly support DZ2002's promising therapeutic potential for dry eye disease (DED).